FDA approves daraxonrasib as Elicio preps Phase 1 trial combining it with camupepimutNov 6Regulatory decisiondaraxonrasibElicio TherapeuticsUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Revolution Medicines' daraxonrasib appears in two new pancreatic cancer trial registrationsOct 27Weekly roundup, 2 itemsdaraxonrasibRevolution Medicines, Inc.
Tango reports 82% response rate for vopimetostat-daraxonrasib combo in pancreatic cancerOct 23Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines draws $250M loan tranche after FDA approves RASONQUEOct 13FinancingdaraxonrasibRevolution Medicines, Inc.
Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancerSep 8Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Johns Hopkins registers Phase 2 trial of Revolution Medicines' daraxonrasib in biliary tract cancerAug 28Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLCAug 20Trial updateRevolution Medicines, Inc.zoldonrasib
Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasibAug 10Trial updatedaraxonrasibRevolution Medicines, Inc.
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Summit reports Q2 2026 results as HARMONi OS data hold up in western patientsJul 23Clinical readoutGlaxoSmithKlineivonescimab